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Vitronectin: Growth Factor Complexes Hold
Potential as a Wound Therapy Approach
Zee Upton1, Leila Cuttle2, Anthony Noble1, Margit Kempf2, Gemma Topping1, Jos Malda1, Yan Xie1,
Julie Mill2, Damien G. Harkin1, Olena Kravchuk2, David I. Leavesley1 and Roy M. Kimble2
Topical administration of growth factors has displayed some potential in wound healing, but variable efficacy,
high doses, and costs have hampered their implementation. Moreover, this approach ignores the fact that
wound repair is driven by interactions between multiple growth factors and extracellular matrix (ECM) proteins.
We report herein that complexes comprising IGF and IGF-binding proteins bound to the ECM protein
vitronectin (VN) significantly enhance cellular functions relevant to wound repair in human skin keratinocytes
in two- and three-dimensional in vitro cell models and are active, even in the presence of wound fluid.
Moreover, these responses require activation of both the IGF receptor and the VN-binding av integrins. Further,
we assessed the complexes as a topical agent in the treatment of deep dermal partial thickness burns in a
porcine model. This pilot study revealed that the complexes may hold promise as a wound healing therapy.
Critically, the significant responses observed in vitro and the encouraging preliminary data in vivo were
obtained with nanogram doses of growth factors. This suggests that coupling delivery of growth factors to ECM
proteins such as VN may ultimately prove to be a more effective strategy for developing a wound healing
therapy.
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INTRODUCTION
Delayed or aberrant wound healing and tissue regeneration
are common co-morbidities of major diseases including
cancer (Wang et al., 2006), cardiovascular disease (Valencia
et al., 2001), and diabetes (Jeffcoate et al., 2004) and is also
observed in patients afflicted with severe burn injuries (Atiyeh
et al., 2005). A number of therapeutic strategies have been
applied with variable success. The topical administration of
growth factors has displayed some potential benefits (Brown
et al., 1989; Fu et al., 1998, 2005; Robson et al., 1998; Rees
et al., 1999; Galiano et al., 2004; Goldman, 2004), but
inconsistent efficacy, high doses, and costs have hampered
their implementation. Moreover, application of individual
growth factors overlooks the evidence that wound repair
in vivo is driven by multiple interactions between growth
factors and extracellular matrix (ECM) molecules (Giancotti
and Ruoslahti, 1999). Our research has therefore focused on
the development of multimeric complexes comprising growth
factors and ECM proteins. This has led to the discovery that
complexes containing IGFs, IGF-binding proteins (IGFBPs),
epidermal growth factor (EGF), and the ECM protein vitro-
nectin (VN) significantly enhance the proliferation and
migration of human keratinocyte cell lines (Hyde et al.,
2004; Hollier et al., 2005), as well as the proliferation of
keratinocytes derived from human tissues (Hollier et al.,
2005; Dawson et al., 2006). Further, we have recently
demonstrated the utility of these complexes in replacing the
requirement for serum and high concentrations of insulin for
the ex vivo expansion and propagation of cells for human
skin (Dawson et al., 2006) and corneal grafts (Ainscough
et al., 2006).
In view of these data, we have extended our studies
to examine the potential of the VN:growth factor complexes
as a topical therapeutic agent in dermal wound repair. We
pursued this as the critical role of the IGF system in skin and
maintenance of epidermal integrity has been extensively
documented (Edmondson et al., 2003; Dawson et al., 2006).
Indeed, the absence of secreted IGF-I in diabetic skin and
ulcer tissue has been proposed to underlie the delayed
wound healing responses observed in diabetic patients
(Blakytny et al., 2000). In addition, the role of IGFBPs
in modulating IGF action is known to have both stimulatory
and inhibitory effects; however, improved healing responses
are observed when IGF-I is co-administered with IGFBPs
to wounds in in vivo rodent or rabbit models (Hamon et al.,
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1993; Jyung et al., 1994; Tsuboi et al., 1995; Galiano et al.,
1996). VN on the other hand also has important roles
in wound healing (Hocking et al., 1999; Jang et al., 2000),
this being comprehensively demonstrated in studies in
VN-knockout mice, which exhibit increased wound fibrino-
lysis and impaired microvascular angiogenesis (Jang et al.,
2000). Further evidence suggests that integrins, especially
av VN-binding integrins, are pivotal in healing processes such
as angiogenesis and migration of keratinocytes and are
upregulated following wounding (Christofidou-Solomidou
et al., 1997).
Because the migration and proliferation of keratinocytes
is a critical process in the re-epithelialization of wounds, and
the EGF and IGF systems, along with VN and the av integrins,
are strongly implicated in wound healing (Hamon et al.,
1993; Jyung et al., 1994; Tsuboi et al., 1995; Galiano et al.,
1996; Christofidou-Solomidou et al., 1997; Hocking et al.,
1999; Blakytny et al., 2000; Jang et al., 2000), we proposed
that the VN:growth factor complexes might hold potential
as a topical wound healing agent. We report herein that
the complexes stimulate functional responses relevant to
wound healing in human keratinocytes in vitro, even in the
presence of high concentrations of chronic wound fluid
(CWF). Secondly, we have demonstrated that the complexes
enhance wound healing-related responses in an in vitro
three-dimensional (3D) human skin equivalent (HSE) model.
Finally, we present data from a small, prospective, rando-
mized, blinded pilot trial examining the topical application of
VN:growth factor complexes to wounds in juvenile pigs.
RESULTS
Migration of keratinocytes derived from human skin is
enhanced in the presence of VN:growth factor complexes
As a first step toward examining the potential of the
VN:growth factor complexes in wound healing, the migration
of keratinocytes derived from human skin was assessed.
This function-based bioassay was chosen as the ability of
keratinocytes to migrate over and re-epithelialize the wound
bed is one of the early, critical responses required for
effective wound healing. Further, we elected to use the
Transwell migration assay since this assesses migration in
terms of chemokinesis, a critical element of the recruitment of
keratinocytes and progenitor cells for re-epithelialization of
wounds (Gillitzer and Goebeler, 2001). These assays
revealed that migration of primary-cultured keratinocytes
added to Transwells with 1 mg of VN pre-bound to the lower
chamber was significantly increased by 2478% compared to
cells seeded in the untreated control (serum-free media
(SFM)) TranswellsTM (Figure 1). The addition of IGF-I (30 ng)þ
IGFBP-3 or -5 (90 ng) without VN increased migration
of these cells by 3978% and 1873% above the control,
respectively. When VN was present, however, migration
increased to 108713% and 96714% above the control for
complexes containing IGF-I in combination with IGFBP-3 or
-5, respectively. In contrast, keratinocytes pre-incubated with
an anti-av integrin antibody responded with similar levels
to that observed for the control, regardless of the presence
of VNþ IGF-Iþ IGFBP-3 or -5. Moreover, when IGF-I in the
complexes was replaced by Leu24-IGF-I, an analog of human
IGF-I with a greatly reduced affinity for binding to the
type-1 IGF receptor (IGF-1R) (Bayne et al., 1990), the level
of migration was also significantly reduced to 37710 and
2577% above the control for complexes containing IGF-I in
combination with IGFBP-3 or -5, respectively.
VN:growth factor complexes stimulate cell proliferation
in the presence of CWF
To further evaluate the potential application of the VN:
growth factor complexes in wound healing, we investigated
the proliferative responses of human keratinocytes to VN
in combination with IGF-I, IGFBP-3, and EGF in the presence
of CWF. Proliferation of keratinocytes is another important
biological response that is required for effective wound
closure. Moreover, if growth factors are to be effective
therapeutics for enhancing wound healing, the growth factors
need to be active in the presence of wound exudate. CWF,
obtained from patients suffering from non-healing leg ulcers,
was therefore included in an attempt to emulate in vitro the
wound microenvironment (Drinkwater et al., 2002) that the
VN:growth factor complex may encounter in vivo if used as
a wound healing therapeutic. Owing to the number of cells
required, the spontaneously immortalized HaCaT human
keratinocyte cell line, which retains many of the essential
features of primary keratinocyte physiology and pathology
(Breitkreutz et al., 1998), was used for this study rather
than human skin-derived primary keratinocytes. In addition,
EGF was included in these and subsequent studies as the
media used for the primary-cultured keratinocytes described
above also contained EGF (Rheinwald and Green, 1975).
Interestingly, a dose-dependent stimulation was observed
in cells cultured in SFM supplemented with CWF (Figure 2).
In the absence of CWF, the VN:growth factor complex
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Figure 1. Stimulation of migration of keratinocytes derived from human
skin by VN, IGF-I, and/or IGFBP-3 or -5. The data, expressed as %
stimulation of the control (serum-free media; SFM), were pooled from three
replicate experiments in which each treatment was tested in duplicate.
To dissect the importance of molecular interactions with the IGF-I and
VN-binding cell surface receptors, an analog of IGF-I that binds poorly to
the type-1 IGF-IR (Leu24-IGF-I) and an anti-av integrin monoclonal antibody
(av-mAB) were used, respectively. Error bars¼mean7SEM, n¼ 9.
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also dramatically stimulated cell proliferation (348728%) in
comparison to the negative control (SFM) as expected.
Moreover, when cultures were treated with the VN:growth
factor complex in the presence of CWF, the stimulatory effect
was retained; cell responses being similar to the additive
effects of the complex and CWF by themselves.
VN:growth factor complexes enhance re-epithelialization in an
in vitro skin equivalent model
The observation that the VN:growth factor complexes were
able to stimulate keratinocytes in vitro, even in the presence
of high concentrations of CWF, provided the impetus to
investigate the effects of the VN:growth factor complex
on re-epithelialization using an in vitro 3D HSE model. Thus,
P1 keratinocytes derived from human skin were seeded
onto a de-cellularized dermal scaffold, as described in the
Materials and Methods section, and epidermopoiesis was
assessed using histomorphometric analysis 4 days after lifting
the HSEs to the air–liquid interface (Figure 3a). This revealed
that a thicker stratified epidermal layer formed on HSEs
topically treated with the VN:growth factor complexes
compared to control-treated HSEs. The increase in thickness
was evident in both the viable and cornified layers and
was dose-dependent, with the 3 VN:growth factor complex
treatment increasing thickness of the layers to a greater extent
than found with the 1 VN:growth factor complex dose.
The differences in thickness of the viable and cornified layers
of HSEs exposed to both doses of the complexes were
significantly greater than the control, with P-valueso0.05 for
both layers of HSEs exposed to the 1 dose, and P-values
o0.01 and 0.005 for the viable and cornified layers of HSEs
exposed to the 3 dose, respectively.
In another series of experiments, burn wounds were
created in the HSEs after being established and cultured at
the air/liquid interface for 8 days and responses to topical
application of the VN:growth factor complexes and control
treatments (SFM alone) were evaluated histomorphologically.
As shown in the representative image in Figure 3b, the HSEs
showed an intact and fully differentiated epidermis with
easily visible nuclei and a normal dermis. The death of
keratinocytes following burning was judged from the
presence of elongated and detached cells from the dermis
and a slightly compacted dermis under the area of the burn
(Topping et al., 2006) (Figure 3b). Two days following
administration of the burn, the keratinocytes were observed
to migrate into the wounded zone and proliferate. Further-
more, a newly formed stratum corneum was evident
beneath the damaged tissue. Following an additional 4 days
of cultivation, the keratinocytes migrated further into the
wound bed and developed a stratified epidermis. The newly
formed epidermis in the wounded HSEs, treated with either
the control solution (SFM alone) or the VN:growth factor
treatment, was assessed by histomorphometry (Figure 3c),
with the area (Figure 3d), lateral migration (Figure 3e), and net
migration (Figure 3f) measured. This revealed that the keratino-
cytes in the newly formed epidermis in wounds treated with
the VN:growth factor complex migrated and proliferated to a
greater extent than those treated with the control solution. The
area (day 4¼ Po0.01, day 6¼ Po0.001), lateral migration
(day 4¼Po0.05, day 6¼Po0.05), and net migration (day
4¼Po0.05, day 6¼ Po0.001) of the keratinocytes was signi-
ficantly greater at both days 4 and 6 post-burn, thus supporting
the quantitative re-epithelialization and cell migration data
reported above.
Topical application of VN:growth factor complexes to wounds
in a porcine model
Encouraged by our two-dimensional and 3D in vitro analyses
of the VN:growth factor complexes, we evaluated the effects
of the complexes on wound closure in a pilot study using an
in vivo burns model. We elected to use our recently
developed porcine model (Cuttle et al., 2006), since pig skin
is known to be anatomically and physiologically most similar
to human skin, and is claimed to be the most reliable model
in terms of ultimate translation of wound healing therapies
to patients (Sullivan et al., 2001).
The animals received deep dermal partial thickness burns
(DDPTBs) on their flanks and were immediately treated with
either the VN:growth factor complexes or sterile water in a
blinded manner. Each animal only received either VN:growth
factor complexes or water control on both wounds to
eliminate any potential systemic effects. The wounds were
dressed with Acticoat7TM (a standard burns dressing) with
dressings changed weekly and repeat treatments adminis-
tered weekly. Silicone catheters were also placed on the
outside of the Acticoat7TM. This facilitates the administration
of water required for correct use of the dressing, as well
as administration of dilute doses of the VN:growth factor
complexes at 1/3 dose, three times per week. Healing was
followed over 6 weeks and the wounds were photographed
and clinically scored. In addition, tissue was collected at
6 weeks for histological, morphological, and anatomical ana-
lysis. One animal in the VN:growth factor complex arm was
euthanized during the study as a result of a rectal prolapse
(which was deemed unrelated to the burn or treatment).
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Figure 2. Stimulation of keratinocyte proliferation in response to wound
fluid in the presence and absence of the complexes. The data, expressed
as % stimulation of the control (serum-free media; SFM), were pooled
from three replicate experiments in which each treatment was tested in
triplicate. Error bars¼mean7SEM, n¼ 9.
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Therefore, three pigs with six wounds were analyzed in
the VN:growth factor complex group and four pigs with eight
wounds were analyzed in the control group.
The analyses revealed that animals treated with the
complexes exhibited significantly faster re-epithelialization
as scored by two blinded, highly experienced burns clinicians
over the duration of the experiment than did the control-
treated animals (P¼ 0.031) (Figure 4a). Nevertheless, histo-
logical assessment of tissue excised from the wounds at the
completion of the experiment found no significant differences
in thickness of epidermis or dermis, total skin thickness, or
hair follicle density between the test and control treatments
(Figure 4b–d). However, as can be seen in Figure 4, a trend
toward a decreased total skin thickness in the VN:growth
factor complex-treated animals is apparent (Figure 4b). This
would appear to result from a trend toward reduced dermal
thickness (Figure 4c) rather than a compromised epidermis
(Figure 4d). Indeed, this trend toward decreased dermal thick-
ness most likely arises from the significant differences in the
quantity of organizing granulation tissue (OGT), as measured
by quantitative histology and expressed as a % of the total
dermis, observed between treatment groups. Thus signi-
ficantly less OGT is evident in the VN:growth factor complex-
treated group (P¼ 0.010) (Figure 4e).
The final cosmetic appearance of the wounds varied, as
would be expected for a pilot trial with a small number of
animals, and as can be seen in Figure 5 where photographic
images of all wounds at week 6 are depicted. Nevertheless in
general, morphological features such as wound contraction,
scar profile, and hair follicle density were considered to be
better overall in the VN:growth factor complex-treated
animals compared to the control-treated animals (Figure 5).
DISCUSSION
The data presented in this study demonstrate that complexes
comprising the ECM protein VN, in combination with IGF-I,
IGFBPs, and EGF hold promise as a wound healing thera-
peutic. Specifically, we show for the first time that the
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Figure 3. Re-epithelialization of 3D in vitro skin equivalent model is enhanced by VN:growth factor complexes. (a) Histological analyses of epithelialization
of a human skin equivalent (HSE) model in the presence of the VN:growth factor complexes or the control solution (serum-free media; SFM). The thickness
of the viable and cornified epidermis was measured. (b) Histological analyses of a HSE model before and after application of a thermal lesion. The dashed
vertical line denotes the margin of the burn. To the right of the line is the burnt area. (c) Schematic representation of the measurements of burn wound
healing in the HSEs analyzed. HSEs were treated with either topical application (every 2 days) of the VN:growth factor complexes or the control solution (SFM).
The dotted line illustrates the parameters measured: area, lateral migration, and net migration of keratinocytes in the (c) wound bed, (d) area, (e) lateral
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VN:growth factor complexes potently stimulate migration
and proliferation of keratinocytes derived from human skin.
This is demonstrated using two-dimensional and 3D in vitro
models. Prior to this report, enhanced migration in response
to these complexes has only been demonstrated in keratino-
cyte cell lines, rather than in cells derived from human tissues
(Hyde et al., 2004). Moreover, we demonstrate for the first
time that the enhanced responses are abrogated when the
cells are incubated with a function-blocking anti-av integrin
antibody, indicating that VN-binding av integrins are crucial
to the enhanced cell migration. The role of IGF-1R is also
implicated since cellular responses to complexes incorporat-
ing the IGF-I analog Leu24-IGF-I (which binds poorly to the
IGF-1R but maintains affinity for IGFBPs; Bayne et al., 1990)
are also significantly reduced. Indeed, the migration res-
ponses observed in the presence of Leu24-IGF-I are similar
to those found with VN alone. Taken together, these data
indicate that ligation of both the VN-binding av integrins and
the IGF-1R is critical for the enhanced migration observed in
response to the complexes.
We also examined the responses of cells to the complexes
in the presence of wound fluid. Wound fluid is believed
to reflect the extracellular microenvironment of the chronic
wound bed and can vary significantly between patients
(Drinkwater et al., 2002). For this reason, we used pooled
CWF samples obtained from 12 different patients in our
experiments as we were seeking to replicate an ‘‘average’’
wound environment. Interestingly, we found that CWF alone
stimulated human keratinocyte cell proliferation, a result that
has been reported by others (He et al., 1999; Trengove et al.,
2000). Conversely, Bucalo et al. (1993) found that CWF
inhibits cellular proliferation; this variable effect of CWF
on cellular behavior presumably reflecting the variability
in CWF between patients. Importantly, however, we demons-
trate that the activity of the VN:growth factor complexes is
still substantial, even in the presence of CWF.
Before assessing the VN:growth factor complexes in vivo,
we examined their wound healing potential in an in vitro 3D
HSE model, since these models reproduce many morpho-
logical characteristics of human skin in defined conditions.
Further, two-dimensional in vitro models have been found to
be poor predictors of in vivo responses (Sun et al., 2006). We
were therefore encouraged by the observation that epithelia-
lization of P1 keratinocytes on a de-cellularized dermal
scaffold in the presence of the VN:growth factor complexes
resulted in a significantly thicker epidermis compared to that
obtained in HSEs treated with the control solution. Further-
more, topical administration of the VN:growth factor
complexes to wounded HSEs stimulated significantly en-
hanced keratinocyte migration and proliferation across the
wound bed in the HSE as measured in terms of area, lateral
migration, and net migration of keratinocytes in the newly
formed epidermis, thereby corroborating our findings from
our two-dimensional in vitro cell migration studies.
Finally, we elected to assess the wound healing potential
of the complexes in a pilot study employing a large animal
in vivo model of a DDPTB. A DDPTB model was selected
as DDPTBs are the most common depth of burn presenting
to pediatric hospitals (Burd and Yuen, 2005) and are the
most difficult burn injury to manage. We employed a porcine
model of DDPTB, as this closely simulates the DDPTBs seen
in children, including the development of contracted, purple
hypertrophic scars, whereas rodent or rabbit models do not
(Cuttle et al. 2006). To improve long-term outcomes for this
patient group and prevent hypertrophic scarring, stimulation
of keratinocytes to accelerate re-epithelialization is theoreti-
cally desirable. In the studies reported herein, the VN:growth
factor complex-treated wounds re-epithelialized significantly
faster than their control counterparts, as scored by two
experienced burns clinicians. Furthermore, a statistically
significant decrease in OGT, as quantitated through histo-
morphometric analysis, was observed in the VN:growth
factor-treated group. These are key features that are associated
with desirable healing in burn wounds. This is based on
the contention that keratinocytes in a re-epithelialized epi-
dermis participate in paracrine signaling with the underlying
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Figure 4. Effect of topical application of the VN:growth factor complexes
on porcine wounds. Burn wounds in juvenile Large White pigs were treated
with Acticoat7TM (a standard burn dressing)7VN:growth factor complexes.
(a) Re-epithelialization was significantly faster (P¼ 0.031) over the duration
of the experiment in the VN:growth factor-treated wounds (refer to scoring
scale in Materials and Methods). (e) There was significantly less organizing
granulation tissue (OGT) in the VN:growth factor complex-treated group
(P¼0.010). There were no significant differences observed in (b) total skin
thickness, (c) dermal thickness, (d) epidermal thickness, or (f) hair follicle
density. Error bars¼mean7SEM, control group n¼4 and VN:growth
factor complex-treated group n¼ 3.
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fibroblasts, resulting in downregulation of collagen produc-
tion by the fibroblasts (Smola et al., 1993; Werner and
Smola, 2001). In addition, OGT, also known as the wound
inflammatory layer or scar tissue layer and containing
proliferating fibroblasts and capillaries, initially is poorly
organized and with time forms a dense scar. Based on clinical
observations, we and others believe that the amount of
OGT in a wound can be an indication of the extent of
later scarring; hence, less OGT is desirable (Zhu et al., 2003;
Cuttle et al., 2006; Harunari et al., 2006), particularly with
pediatric burns. Nevertheless, the hypothesized beneficial
effects of the VN:growth factor complexes on OGT and on
the final scar outcome would need to be proven by further
longitudinal studies. In addition, our future DDPTB studies in
pigs will use a greater number of animals to determine
whether some of the ‘‘trends’’ observed in this pilot study are
statistically significant when a larger cohort is assessed.
The topical application of growth factors to dermal
wounds has been documented in several previously reported
studies (Brown et al., 1989; Fu et al., 1998, 2005; Rees et al.,
1999; Galiano et al., 2004); however, these approaches have
generally used supraphysiological doses of growth factors,
ranging from 1 to 70 mg cm1 (Robson et al., 1992a, b, 2001;
Valencia et al., 2001; Galiano et al., 2004). For example, a
topical dose of vascular endothelial growth factor at
70 mg cm2 was recently shown to be effective in a rat study
(Galiano et al., 2004), providing the impetus for a current
clinical trial of topical application of vascular endo-
thelial growth factor for diabetic foot ulcers, presumably also
using similar large doses. As a consequence, high costs are
associated with these therapies, limiting their widespread
clinical implementation. As described in this study, we have
developed an alternative therapeutic approach that involves
combining growth factors with ECM proteins, resulting in a
promising growth factor-based treatment that uses nanogram
quantities, that is physiologically relevant doses, for the first
time. Indeed, the doses of growth factors in this study are less
than 1/10th–1/2,000th of those previously trialed by others,
and importantly, were applied weekly, not daily as is
generally reported by others. While diluted doses (1/3
dose) of the VN:growth factor complex were applied via
catheters three times per week, we are not confident that the
treatments administered in this manner were actually
delivered to the wound bed, since the catheters delivered
the water7treatment to the top of the Acticoat7TM dressing.
Moreover, we believe that the less frequent application of
growth factors to wounds, as adopted in our study, may
confer benefits in terms of minimizing downregulation of
growth factor receptors present on the cells in the wound.
Downregulation of receptors, and in turn downregulation of
intracellular signaling, are well-described outcomes of
prolonged exposure to growth factors (Rubin et al., 2005)
and may explain why daily topical administration of
supraphysiological doses of growth factors to wounds has
met with limited and variable success. Further, the effective-
ness of the nanogram doses of growth factors may arise from
the ability of VN to ‘‘store’’ bound growth factors in tissues
and/or to protect the growth factors from degradation; this
latter idea supported by our finding that the activity of the
complexes was not hampered by the presence of CWF.
Alternatively, the intimate association of VN with the surface
of cells via interactions with integrins may also facilitate
localization of the bound growth factors in close vicinity with
their cognate receptors present on the cell surface. Indeed,
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Figure 5. Photographic images of the control vs VN:growth factor complex-treated wounds. Photographs of wounds on both the left and right
flanks of all animals after 6 weeks of treatment. Photographs on the left show wounds in the four control-treated animals (Acticoat7
TM
), whereas those on the
right show wounds from the three VN:growth factor-treated animals (Acticoat7TMþVN:growth factor complex). Scale bar¼2 cm.
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our recent investigations have indicated that the co-activation
of the IGF-1R receptor as well as the VN-binding av integrins
results in enhanced intracellular signaling (Hollier B,
Kricker JA, Van Lockhuyzen D, Leavesley DI, Upton Z)
Substrate-bound IGF:IGFBP:vitronectin-stimulated breast cell
migration requires co-activation of the PI3-K/AKT pathway
by av-integrin and the IGF-1R. Submitted). Regardless of the
mechanisms underlying the effectiveness of the complexes,
the development of a wound healing therapeutic that only
requires nanogram doses of growth factors clearly has
considerable advantages in terms of cost.
Taken together, these findings suggest that the VN:growth
factor complexes may ultimately prove be an effective topical
treatment for burns and that growth factors bound to integrin-
activating ECM proteins such as VN may offer a more effec-
tive way to present growth factors to cells for tissue repair
and regeneration applications. Indeed, VN binds a range of
growth factors and exists in a multimeric state in the
extracellular environment; hence, many VN:growth factor
macromolecular complexes (Seiffert and Loskutoff, 1996) are
clearly possible, in turn facilitating the delivery of multiple
mitogenic agents to cells in wounds. For example, EGF,
platelet-derived growth factor, and transforming growth
factor-b have been implicated in the wound healing process
and have been found to bind to VN (Heldin et al., 1981;
Wijelath et al., 2000; Schoppet et al., 2002). Further, platelet-
derived growth factor and EGF have been demonstrated to
synergize with IGF-I to enhance keratinocyte proliferation
(Lynch et al., 1989; Krane et al., 1991). Thus, multimeric VN
complexes containing not only IGF but also other growth-
promoting agents represent a multifactorial growth factor
delivery approach that appears to confer significant addi-
tional benefits as a wound therapeutic.
MATERIALS AND METHODS
Cell isolation and culture
Skin samples were collected from consenting patients undergoing
breast or abdomen reductions at the St Andrews and Wesley
Hospitals (Brisbane, QLD, Australia). Human ethical approval
was obtained from both hospitals and the Queensland University
of Technology. In addition, all experiments were conducted
in accordance with the Declaration of Helsinki 2004. Human
keratinocytes were isolated from the skin samples and cultivated
in vitro in Green’s medium (Rheinwald and Green, 1975) following
previously described protocols (Dawson et al., 2006). Keratinocytes
up to passage 4 were used for the migration and proliferation studies
reported herein. HaCaT human keratinocyte cells, obtained from
Professor Norbert E. Fusenig (DKFZ, Heidelberg, Germany), were
routinely grown as described previously (Hyde et al., 2004).
Cell migration assay
Migration was quantified over 5 hours using the TranswellTM
(12.0mm pore; Costar, New York, NY) migration assay (Leavesley
et al., 1993; Hyde et al., 2004). Human keratinocytes were
incubated in SFM for 12 hours prior to the assay. For the migration
and proliferation assays, IGF-I (GroPep Ltd, Adelaide, S.A., Australia)
and IGFBP-3 (R&D Systems, Minneapolis, MN) or IGFBP -5 (Dr Sue
Firth, The University of Sydney, Sydney, Australia) were pre-bound
to VN (Promega, Madison, WI) in the lower chamber of the
TranswellTM as described previously (Noble et al., 2003; Hyde et al.,
2004). An analog of IGF-I (Leu24-IGF-I) (GroPep), which has a lower
affinity for the IGF-1R than native IGF-I (Bayne et al., 1990), and an
anti-av integrin monoclonal antibody (1:10; Chemicon, Temecula,
CA) were used to dissect the importance of molecular interactions
with IGF-binding and VN-binding cell surface receptors.
Cell proliferation assay
To evaluate the effects of CWF on the activity of the VN:growth
factor complexes, CyQuant assays (Invitrogen, Mulgrave, N.S.W.,
Australia) were conducted in 48-well plates (500 ml per well, final
volume) to quantify HaCaT human keratinocyte cell proliferation
over 48 hours in the presence and absence of VN (162 ng per
well)þ IGF-I (54 ng per well)þ IGFBP-3 (162 ng per well)þ EGF
(54 ng per well) and increasing amounts (0–0.081mg per well)
of CWF. Cells were incubated in SFM for 4 hours prior to the
assay. CWF was collected from 12 consenting patients of the
St Lukes Nursing Services (Brisbane, QLD, Australia) suffering
from chronic venous ulcers. Ethical approval to collect these
samples was obtained from both the St Luke’s Nursing Services
and the Queensland University of Technology. CWF was collected
by applying an occlusive film dressing (OpSite, Smith & Nephew,
Hull, UK) for 1–2 hours over the chronic ulcer. The exudate, which
collected under the film, was removed using a syringe. The samples
were centrifuged at 14,000 g for 10minutes and then the supernatant
filtered using 0.45mm cellulose acetate filters (Agilent Technologies,
Wilmington, DE). The protein content in the supernatant was
determined using a BCA Protein assay kit (Pierce Biotechnology,
Rockford, IL) prior to aliquotting and storage at 801C until
further use.
3D in vitro skin equivalent model
3D HSEs, based on a de-cellularized de-epidermized dermis,
were prepared from donor skin of consenting patients following
previously described protocols (Chakrabarty et al., 1999). Briefly, the
de-epidermized dermis pieces were trimmed to approximately
1.4 cm 1.4 cm and placed papillary side upward in a 24-well
culture plate. Sterile stainless-steel rings (Aix Scientifics, Aachen,
Germany) with a silicone washer base and a diameter of 7mm were
placed on top of the de-epidermized dermis. P1 keratinocytes
(1.9 104 cells) suspended in 200ml of culture medium containing
serum were added to each ring and the de-epidermized dermis
pieces were incubated at 37 1C and 5% CO2. After 1 day, the
rings were removed and the HSEs (dermis plus keratinocytes) were
elevated to the air–liquid interface by transferring the composites
to a stainless-steel grid in a six-well culture plate maintained
in keratinocyte culture medium containing serum at 37 1C and
5% CO2.
For the epithelialization studies, HSE composites were treated
with a topical application of 20 ml of SFM or 20 ml of SFM containing
a 1 dose (15 ng IGF-I, 15 ng EGF, 44 ng IGFBP-3, 44 ng VN) or a
3 dose (45 ng IGF-I, 45 ng EGF, 132 ng IGFBP-3, 132 ng VN) of the
VN:growth factor complexes at the time of lifting to the air–liquid
interface and 2 days after lifting. For each treatment, three separate
HSEs were evaluated, with three independent replicates of the
experiment performed using cells derived from a different patient.
After 4 days of culture at the air–liquid interface, the HSEs were fixed
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in 10% formalin and dehydrated in a graded ethanol series.
Samples were embedded in paraffin and cut to yield 5-mm-thick
cross-sections. Sections were stained with hematoxylin and eosin
(Sigma-Aldrich; Castle Hill, N.S.W., Australia) for further histological
analysis. The thickness of the cornified and viable epidermis was
determined from four consecutive images acquired in the center
of the reconstructed dermis using a digital camera (Nikon DXM
1200; Maxwell Optical; Homebush, N.S.W., Australia) mounted
on a microscope (Leitz Laborlux S; Leica Microsystems, Gladesville,
NSW, Australia). The average thickness (mm) of the layers was
measured using Scion Image software (Scion Corporation, Frederick,
MD) by averaging 10 measurements per image.
In a separate series of experiments, the HSEs were cultured for
8 days at the air–liquid interface using serum-containing media and
then thermal lesions were introduced using a heated 0.32 cm2 base
stainless-steel rod, as described elsewhere (Topping et al., 2006). A
topical application of 20 ml of SFM or 20 ml of SFM containing IGF-I
(15 ng)þ EGF (15 ng)þ IGFBP-3 (44 ng)þVN (44 ng) was applied to
the composites every 2 days for up to a total of 6 days. Subsequently,
samples were fixed and embedded in paraffin using standard
procedures and processed for hematoxylin and eosin histological
analysis. To quantitatively assess the formation of new epidermis
underlying the burn, the following parameters were measured using
ImageJ software (National Institutes of Health): area of newly formed
epidermis, lateral migration of the keratinocytes, and net migration
of keratinocytes along the basement membrane. For each HSE, two
sections cut through the center of the wound were assessed with two
independent measures of each parameter obtained for each section
and with three replicate HSEs per treatment.
Pilot study using an in vivo porcine burn model
Animal protocols were approved by the Animal Ethics Research
committees of the Queensland University of Technology and
the University of Queensland. DDPTBs with a 8.5 cm diameter
were created on both mid-flanks of eight large white juvenile
pigs as described in detail elsewhere (Cuttle et al., 2006). After
wounding, four animals received a topical treatment of VN
(132 ng cm2)þ IGFBP-3 (132 ng cm2)þ IGF-I (44 ng cm2)þ EGF
(44 ng cm2) in 5ml of sterile water applied directly to the wounds,
while the four control animals received a treatment of sterile water
alone. Acticoat7TM (Smith & Nephew) dressings were then applied to
the wound and a silicone catheter placed on the outside of the
Acticoat7TM to allow administration of 5ml water (three times per
day) as well as the VN:growth factor complexes (at 1/3 dose, three
times per week). We elected to use Acticoat7TM, a nanocrystalline
silver dressing with broad spectrum antimicrobial activity, because it
is the most commonly applied wound dressing in our burns center
(Rustogi et al., 2005) and allows infrequent dressing changes with
minimal discomfort. All wounds were then dressed with MelolinTM
and FixomullTM (both Smith & Nephew) and dressings were changed
weekly. The animals were studied for 6 weeks and wounds were
photographed weekly. The digital photographs were examined
(independently and fully blinded) by two experienced burns clini-
cians and graded using the following criteria: (a) wound contraction
(0¼ normal, 1¼minor, 2¼moderate, 3¼ severe); (b) presence of
hair (0¼ normal, 1¼ some hair missing, 2¼most hair missing, 3¼
all hair missing); (c) re-epithelialization (0¼ 100%, 1¼ 90–100%,
2¼ 50–90%, 3¼o50%); (d) scar (0¼ normal, 1¼ pink, 2¼ red,
3¼ purple); and (e) scar profile (0¼ flat, 1¼minor raising (p1mm),
2¼moderate raising (p2mm), 3¼ severe raising (42mm). Samples
of damaged tissue and control tissue were recovered from each
wound area of the euthanized animals at 6 weeks, and were fixed
and embedded in paraffin using standard procedures prior to
processing for histological analysis. The depth of epidermis, dermis,
OGT as a percentage of the dermis, and density of hair was
determined as described previously (Cuttle et al., 2006). For each
wound, four sections of non-injured skin were collected approxi-
mately 5 cm from the dorsal, ventral, cranial, and caudal wound
borders. Seven sections of skin were taken from the burn area,
horizontally and vertically, in a cross pattern across the wound.
Statistical analysis
All in vitro experiments were conducted with either duplicate or
triplicate treatments as indicated in the figure legends and the entire
experiments were repeated three times. When human cells isolated
from skin were used, each replicate experiment was performed with
cells derived from different donors. Results are given as mean7SEM.
Two-tailed Student’s t-test (in vitro studies) or analysis of variance
(in vivo studies) was performed to test for significance. The level of
statistical significance was set at Po0.05.
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